In 2024, the FMBA of Russia (Federal Medical and Biological Agency) intends to create in the country the production of a drug with the active substance ataluren, which is used to combat Duchenne muscular dystrophy. At the moment, a sample of the pharmaceutical substance has already been developed, said Igor Berzin, head of the department for organizing scientific research of the department, during a meeting in the Federation Council.
According to him, FMBA has set a course for the development of complex generics for the needs of the state fund “Circle of Good,” which sponsors the treatment of children with orphan diseases. At the same time, the cost of Russian analogues can be 20-25% lower compared to foreign reference drugs.
“Based on the results of a joint study with the Circle of Good Foundation, a list of drugs has been determined that meet the needs of the foundation,” Berzin added, clarifying that we are talking about full-cycle production. He did not specify what other medications were included in the list.
Currently, the Circle of Good Foundation cares for 387 children with Duchenne muscular dystrophy; For them, four pathogenetic therapy drugs with proven effectiveness and safety were purchased: ataluren, viltolarsen, golodirsen, eteplirsen and one type of technical rehabilitation means – dynamic parapodium.
